These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18723285)

  • 1. Profound reduction of somatic and visceral pain in mice by intrathecal administration of the anti-migraine drug, sumatriptan.
    Nikai T; Basbaum AI; Ahn AH
    Pain; 2008 Oct; 139(3):533-540. PubMed ID: 18723285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain.
    Kayser V; Aubel B; Hamon M; Bourgoin S
    Br J Pharmacol; 2002 Dec; 137(8):1287-97. PubMed ID: 12466238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.
    Tfelt-Hansen P; De Vries P; Saxena PR
    Drugs; 2000 Dec; 60(6):1259-87. PubMed ID: 11152011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of inflammation-induced thermal hypersensitivity by sumatriptan through activation of 5-HT(1B/1D) receptors.
    Bingham S; Davey PT; Sammons M; Raval P; Overend P; Parsons AA
    Exp Neurol; 2001 Jan; 167(1):65-73. PubMed ID: 11161594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine.
    Winner P; Ricalde O; Le Force B; Saper J; Margul B
    Arch Neurol; 1996 Feb; 53(2):180-4. PubMed ID: 8639069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients.
    Ferrari A; Pinetti D; Bertolini A; Coccia C; Sternieri E
    Eur J Clin Pharmacol; 2008 May; 64(5):489-95. PubMed ID: 18180912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical applications of new therapeutic deliveries in migraine.
    Dahlöf C
    Neurology; 2003 Oct; 61(8 Suppl 4):S31-4. PubMed ID: 14581656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.
    Ferrari MD; Goadsby PJ; Roon KI; Lipton RB
    Cephalalgia; 2002 Oct; 22(8):633-58. PubMed ID: 12383060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The triptan formulations : how to match patients and products.
    Rapoport AM; Tepper SJ; Bigal ME; Sheftell FD
    CNS Drugs; 2003; 17(6):431-47. PubMed ID: 12697002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sumatriptan (5-HT1B/1D-agonist) causes a transient allodynia.
    Linde M; Elam M; Lundblad L; Olausson H; Dahlöf CG
    Cephalalgia; 2004 Dec; 24(12):1057-66. PubMed ID: 15566420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological synergy: the next frontier on therapeutic advancement for migraine.
    Blumenfeld A; Gennings C; Cady R
    Headache; 2012 Apr; 52(4):636-47. PubMed ID: 22221151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of the use of triptans in acute migraine.
    Gawel MJ; Worthington I; Maggisano A
    Can J Neurol Sci; 2001 Feb; 28(1):30-41. PubMed ID: 11252291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous allodynia and migraine: another view.
    Dahlöf C
    Curr Pain Headache Rep; 2006 Jun; 10(3):231-8. PubMed ID: 18778579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triptans: are they all the same?
    Pringsheim T; Gawel M
    Curr Pain Headache Rep; 2002 Apr; 6(2):140-6. PubMed ID: 11872185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Divergent peripheral effects of pituitary adenylate cyclase-activating polypeptide-38 on nociception in rats and mice.
    Sándor K; Bölcskei K; McDougall JJ; Schuelert N; Reglodi D; Elekes K; Petho G; Pintér E; Szolcsányi J; Helyes Z
    Pain; 2009 Jan; 141(1-2):143-50. PubMed ID: 19091468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sumatriptan. An updated review of its use in migraine.
    Perry CM; Markham A
    Drugs; 1998 Jun; 55(6):889-922. PubMed ID: 9617601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sumatriptan: pharmacological basis and clinical results.
    Dahlöf CG
    Curr Med Res Opin; 2001; 17 Suppl 1():s35-45. PubMed ID: 12463276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fast non-genomic effects of progesterone-derived neurosteroids on nociceptive thresholds and pain symptoms.
    Charlet A; Lasbennes F; Darbon P; Poisbeau P
    Pain; 2008 Oct; 139(3):603-609. PubMed ID: 18614289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triptans. A support to the central link between serotonin and acetylcholine in migraine.
    Nicolodi M; Sicuteri F
    Adv Exp Med Biol; 1999; 467():183-9. PubMed ID: 10721055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WITHDRAWN: Oral sumatriptan for acute migraine.
    McCrory DC; Gray RN
    Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD002915. PubMed ID: 22336784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.